UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ELVN holding history
Enliven Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ELVN overviewAll 13F holders of ELVNFull Q2 2026 holdings
- Shares (Q2 2026)
- 342,115
- Value
- $17.4M
- % of portfolio
- <0.1%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 342,115 | $17.4M | <0.1% | +58,571+20.7% | Added | Holders |
| Q1 2026 | 283,544 | $11.1M | <0.1% | +225,676+390.0% | Added | Holders |
| Q4 2025 | 57,868 | $891.2K | <0.1% | −21,640−27.2% | Reduced | Holders |
| Q3 2025 | 79,508 | $1.63M | <0.1% | −58,772−42.5% | Reduced | Holders |
| Q2 2025 | 138,280 | $2.77M | <0.1% | +67,844+96.3% | Added | Holders |
| Q1 2025 | 70,436 | $1.39M | <0.1% | −16,752−19.2% | Reduced | Holders |
| Q4 2024 | 87,188 | $1.96M | <0.1% | +59,506+215.0% | Added | Holders |
| Q3 2024 | 27,682 | $707.0K | <0.1% | +7,564+37.6% | Added | Holders |
| Q2 2024 | 20,118 | $470.2K | <0.1% | −6,717−25.0% | Reduced | Holders |
| Q1 2024 | 26,835 | $472.0K | <0.1% | +26,835 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −105−100.0% | Sold out | Holders |
| Q3 2023 | 105 | $1.43K | <0.1% | +24+29.6% | Added | Holders |
| Q2 2023 | 81 | $1.65K | <0.1% | −253−75.7% | Reduced | Holders |
| Q1 2023 | 334 | $7.32K | <0.1% | −2,511−88.3% | Reduced | Holders |
| Q4 2022 | 2,845 | $11.6K | <0.1% | +2,845 | New | Holders |
| Q1 2022 | 0 | $0 | 0.0% | −4,485−100.0% | Sold out | Holders |
| Q4 2021 | 4,485 | $10.0K | <0.1% | +4,485 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −2,143−100.0% | Sold out | Holders |
| Q2 2021 | 2,143 | $17.0K | <0.1% | +504+30.8% | Added | Holders |
| Q1 2021 | 1,639 | $14.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.